Document Type
Journal Article
Publication Date
2017
Journal
Oncotarget
Volume
8
Issue
53
Inclusive Pages
91654-91661
DOI
10.18632/oncotarget.21560
Abstract
Caveolin-1(CAV-1) was demonstrated to be a tumor suppressor gene and be implicated in the development of breast cancer (BC). Numerous potentially functional polymorphisms in CAV-1 have been identified, but their effects on BC were not clear. This case-control study aims to evaluate the relationship between CAV-1 polymorphisms and BC risk. 560 BC patients and 583 healthy controls were enrolled in the present study, all from Chinese Han population. We detected 3 single nucleotide polymorphisms (rs3807987, rs1997623, and rs7804372) in CAV-1 using the Sequenom MassARRAY method. The association between CAV-1genotypes and BC risk was assessed in six genetic models by calculating the odds ratio (OR) and 95% confidence intervals (95% CIs) with χ2-test. The CAV-1rs3807987 polymorphism was observed to increase the risk of BC And the A allele of rs3807987 relates to a larger tumor size (≥2cm) and lower incidence of PR-positive BC while the AA genotype of rs7804372 associates with a higher ER and Her-2 positive rate among BC patients. In addition, Ars1997623Grs3807987Trs7804372 haplotype was linked to a decreased risk of BC (OR =0.64, 95%CI=0.44-0.93), whereas Crs1997623Ars3807987Trs7804372 haplotype was related to an increased BC risk (OR =1.74, 95%CI=1.04-2.92). Our study suggests that CAV-1 rs3807987 can increase the BC risk among Chinese Han women. And the rs3807987 and rs7804372 in CAV-1 may serve as predictors for prognosis of BC.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
APA Citation
Wang, M., Tian, T., Ma, X., Zhu, W., Guo, Y., Duan, Z., Fan, J., Lin, S., Liu, K., Zheng, Y., Sheng, Q., Dai, Z. J., & Peng, H. (2017). Genetic Polymorphisms in Caveolin-1 Associate with Breast Cancer Risk in Chinese Han Population. Oncotarget, 8 (53). http://dx.doi.org/10.18632/oncotarget.21560
Peer Reviewed
1
Open Access
1
Comments
Reproduced with permission of Impact Journals LLC. Oncotarget